Saroja Pharma Industries India Limited (NSE:SAROJA)
India · Delayed Price · Currency is INR 40.00
0.00 (0.00%)
Nov 8, 2026, 2:47 PM IST
NSE:SAROJA Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 701.29 | 537.27 | 406.69 | 501.93 | 556.33 |
| 701.29 | 537.27 | 406.69 | 501.93 | 556.33 | |
Revenue Growth | 30.53% | 32.11% | -18.97% | -9.78% | 51.75% |
Cost of Revenue | 638.26 | 485.81 | 356.43 | 452.96 | 503.52 |
Gross Profit | 63.03 | 51.46 | 50.27 | 48.97 | 52.8 |
Selling, General & Admin | 13.85 | 15.14 | 16.43 | 15.57 | 13.36 |
Other Operating Expenses | 10.97 | 7.68 | 6.85 | 5.59 | 16.85 |
Operating Expenses | 25.93 | 23.96 | 24.22 | 21.83 | 30.66 |
Operating Income | 37.11 | 27.5 | 26.04 | 27.14 | 22.14 |
Interest Expense | -12.5 | -12.17 | -12.8 | -9.95 | -6.66 |
Interest & Investment Income | 0.28 | 0.36 | 0.24 | 0.13 | 0.1 |
Currency Exchange Gain (Loss) | 0.43 | 0.72 | 0.28 | 0.84 | 1.58 |
Other Non Operating Income (Expenses) | -2.12 | -1.92 | -1.7 | -3.25 | -1.36 |
EBT Excluding Unusual Items | 23.2 | 14.49 | 12.07 | 14.92 | 15.79 |
Gain (Loss) on Sale of Assets | -0.87 | - | - | - | - |
Pretax Income | 22.33 | 14.49 | 12.07 | 14.92 | 15.79 |
Income Tax Expense | 6.19 | 4.15 | 3.29 | 4.31 | 4.39 |
Net Income | 16.14 | 10.34 | 8.78 | 10.61 | 11.4 |
Net Income to Common | 16.14 | 10.34 | 8.78 | 10.61 | 11.4 |
Net Income Growth | 56.10% | 17.75% | -17.19% | -6.97% | 55.90% |
Shares Outstanding (Basic) | 4 | 4 | 4 | 3 | 3 |
Shares Outstanding (Diluted) | 4 | 4 | 4 | 3 | 3 |
Shares Change | - | 13.89% | 20.16% | 2.16% | 5.73% |
EPS (Basic) | 4.02 | 2.57 | 2.49 | 3.61 | 3.96 |
EPS (Diluted) | 4.02 | 2.57 | 2.49 | 3.61 | 3.96 |
EPS Growth | 56.24% | 3.29% | -31.08% | -8.84% | 47.28% |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -42.84 | -14.46 | -37.04 | -15.34 | -39.76 |
Free Cash Flow Per Share | -10.65 | -3.60 | -10.49 | -5.22 | -13.83 |
Gross Margin | 8.99% | 9.58% | 12.36% | 9.76% | 9.49% |
Operating Margin | 5.29% | 5.12% | 6.40% | 5.41% | 3.98% |
Profit Margin | 2.30% | 1.93% | 2.16% | 2.11% | 2.05% |
Free Cash Flow Margin | -6.11% | -2.69% | -9.11% | -3.06% | -7.15% |
EBITDA | 38.21 | 28.64 | 26.98 | 27.8 | 22.56 |
EBITDA Margin | 5.45% | 5.33% | 6.63% | 5.54% | 4.06% |
D&A For EBITDA | 1.1 | 1.14 | 0.94 | 0.65 | 0.42 |
EBIT | 37.11 | 27.5 | 26.04 | 27.14 | 22.14 |
EBIT Margin | 5.29% | 5.12% | 6.40% | 5.41% | 3.98% |
Effective Tax Rate | 27.70% | 28.64% | 27.24% | 28.89% | 27.81% |
Revenue as Reported | 702.38 | 539.12 | 408.63 | 503.51 | 559.57 |
Advertising Expenses | 0.89 | 1.38 | 1 | 1.14 | 1.2 |